- Company Directors - R
- Rubin Marc
Insider Trading History of Rubin Marc
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Rubin Marc since 2008.
The trader's CIK number is 1412377.
At the time of the last reporting, Rubin Marc was the President & Chief Ex of Galectin Therapeutics Inc. (stock ticker symbol GALT).
Also see all insider trading activities at Galectin Therapeutics Inc.
Note that in the past
Rubin Marc also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Curis Inc (CRIS) by Rubin Marc
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | CRIS | 0 | $0 | 18,500 | $19,480 | 0 | $0 |
| 2017 | CRIS | 25,000 | $24,500 | 0 | $0 | 0 | $0 |
| 2010 | CRIS | 26,596 | $50,266 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Titan Pharmaceuticals Inc (TTNP) by Rubin Marc
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2018 | TTNP | 400,000 | $100,000 | 0 | $0 | 0 | $0 |
| 2016 | TTNP | 5,000 | $16,250 | 0 | $0 | 0 | $0 |
| 2015 | TTNP | 50,000 | $35,750 | 0 | $0 | 0 | $0 |
| 2014 | TTNP | 100,000 | $48,200 | 0 | $0 | 0 | $0 |
| 2013 | TTNP | 50,000 | $22,700 | 0 | $0 | 0 | $0 |
| 2011 | TTNP | 38,400 | $48,921 | 0 | $0 | 0 | $0 |
| 2008 | TTNP | 30,000 | $40,039 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Galectin Therapeutics Inc (GALT) by Rubin Marc
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | GALT | 0 | $0 | 51,185 | $307,733 | 44,185 | $105,602 |
| 2018 | GALT | 0 | $0 | 70,000 | $431,560 | 35,000 | $0 |
| 2017 | GALT | 7,000 | $12,971 | 0 | $0 | 0 | $0 |
| 2013 | GALT | 3,000 | $26,070 | 0 | $0 | 0 | $0 |
| 2011 | GALT | 20,000 | $19,200 | 0 | $0 | 0 | $0 |
Insider trading activities at 3 companies by Rubin Marc:
1. Curis Inc (CRIS)
2. Titan Pharmaceuticals Inc (TTNP)
3. Galectin Therapeutics Inc (GALT)
Table 1. Insider trading of Curis Inc (CRIS) by Rubin Marc
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-01-23 | CRIS | Sale | 18,500 | 1.05 | 19,480 |
| 2017-11-16 | CRIS | Buy | 25,000 | .98 | 24,500 |
| 2010-12-10 | CRIS | Buy | 26,596 | 1.89 | 50,266 |
Table 2. Insider trading of Titan Pharmaceuticals Inc (TTNP) by Rubin Marc
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2018-09-21 | TTNP | Buy | 400,000 | .25 | 100,000 |
| 2016-01-11 | TTNP | Buy | 5,000 | 3.25 | 16,250 |
| 2015-08-28 | TTNP | Buy | 50,000 | .71 | 35,750 |
| 2014-10-09 | TTNP.OB | Buy | 100,000 | .48 | 48,200 |
| 2013-06-17 | TTNP.OB | Buy | 50,000 | .45 | 22,700 |
| 2011-11-18 | TTNP.OB | Buy | 38,400 | 1.27 | 48,921 |
| 2008-02-05 | AMEX - TTP | Buy | 10,000 | 1.38 | 13,799 |
| 2008-02-06 | AMEX - TTP | Buy | 15,000 | 1.31 | 19,695 |
| 2008-02-07 | AMEX - TTP | Buy | 5,000 | 1.31 | 6,545 |
Table 3. Insider trading of Galectin Therapeutics Inc (GALT) by Rubin Marc
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-02-21 | GALT | Option Ex | 43,326 | 2.39 | 103,549 |
| 2019-02-22 | GALT | Option Ex | 859 | 2.39 | 2,053 |
| 2019-02-21 | GALT | Sale | 50,326 | 6.01 | 302,559 |
| 2019-02-22 | GALT | Sale | 859 | 6.02 | 5,174 |
| 2018-09-04 | GALT | Option Ex | 6,000 | .00 | 0 |
| 2018-09-04 | GALT | Sale | 11,900 | 6.58 | 78,254 |
| 2018-08-30 | GALT | Sale | 58,100 | 6.08 | 353,306 |
| 2018-08-30 | GALT | Option Ex | 29,000 | .00 | 0 |
| 2017-12-08 | GALT | Buy | 7,000 | 1.85 | 12,971 |
| 2013-12-04 | GALT | Buy | 3,000 | 8.69 | 26,070 |
| 2011-10-18 | GALT.OB | Buy | 20,000 | .96 | 19,200 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Rubin Marc
(President & Chief Ex of Galectin Therapeutics Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.